Background: Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma. Skin-directed therapies, including phototherapy, are the first-line treatment modalities. Psoralen plus ultraviolet A light photochemotherapy (PUVA) is quite effective in controlling the disease; however, long-term adverse effects, particularly carcinogenesis, are the cons of this treatment.
Objective: There are various studies on the negative impact of PUVA on skin cancer in patients with autoimmune skin diseases. The data on the long-term effects of phototherapy on MF patients are scarce.
Methods: All MF cases that received PUVA alone or combined with other treatments at a single tertiary center were analyzed. This study compared the development of non-melanoma skin cancers, melanoma, and solid organ tumors in MF patients with at least 5-year follow-up data with age- and sex-matched controls.
Results: A total of 104 patients were included in the study. Ninety-two malignancies were detected in 16 (15.4%) patients, and six developed multiple malignancies. Skin cancers consisted of 56 basal cell carcinomas, 16 Bowen's disease, four squamous cell carcinomas, three melanomas, two basosquamous cell carcinomas, one Kaposi sarcoma, and one keratoacanthoma were found in nine (8.7%) patients. Eight patients developed three solid cancers and six lymphomas. The risk of developing skin cancer was associated with the total number of PUVA sessions (<250 vs ≥250 sessions; hazard ratio (HR) 4.44, 95% confidence interval (CI) 1.033-19.068; p = .045). 9 (13.2%) of 68 patients who had follow-ups for at least 5 years developed skin cancer. Compared to an age- and sex-matched cohort, the prevalence of new skin cancer was considerably greater (p = .009).
Conclusions: Patients with MF are predisposed to develop secondary malignancies, and continual exposure to PUVA may potentiate this risk. Annual digital dermoscopic follow-up in MF patients treated with UVA is advised for early diagnosis and treatment of secondary cutaneous malignancies.
{"title":"Risk of skin cancers in mycosis fungoides patients receiving PUVA therapy: A real-life experience from a single tertiary center.","authors":"Ertop Doğan Pelin, Bengü Nisa Akay, Vural Seçil, Arı Canan, Ertürk Yılmaz Tuğçe, Şanlı Hatice","doi":"10.1111/phpp.12872","DOIUrl":"https://doi.org/10.1111/phpp.12872","url":null,"abstract":"<p><strong>Background: </strong>Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma. Skin-directed therapies, including phototherapy, are the first-line treatment modalities. Psoralen plus ultraviolet A light photochemotherapy (PUVA) is quite effective in controlling the disease; however, long-term adverse effects, particularly carcinogenesis, are the cons of this treatment.</p><p><strong>Objective: </strong>There are various studies on the negative impact of PUVA on skin cancer in patients with autoimmune skin diseases. The data on the long-term effects of phototherapy on MF patients are scarce.</p><p><strong>Methods: </strong>All MF cases that received PUVA alone or combined with other treatments at a single tertiary center were analyzed. This study compared the development of non-melanoma skin cancers, melanoma, and solid organ tumors in MF patients with at least 5-year follow-up data with age- and sex-matched controls.</p><p><strong>Results: </strong>A total of 104 patients were included in the study. Ninety-two malignancies were detected in 16 (15.4%) patients, and six developed multiple malignancies. Skin cancers consisted of 56 basal cell carcinomas, 16 Bowen's disease, four squamous cell carcinomas, three melanomas, two basosquamous cell carcinomas, one Kaposi sarcoma, and one keratoacanthoma were found in nine (8.7%) patients. Eight patients developed three solid cancers and six lymphomas. The risk of developing skin cancer was associated with the total number of PUVA sessions (<250 vs ≥250 sessions; hazard ratio (HR) 4.44, 95% confidence interval (CI) 1.033-19.068; p = .045). 9 (13.2%) of 68 patients who had follow-ups for at least 5 years developed skin cancer. Compared to an age- and sex-matched cohort, the prevalence of new skin cancer was considerably greater (p = .009).</p><p><strong>Conclusions: </strong>Patients with MF are predisposed to develop secondary malignancies, and continual exposure to PUVA may potentiate this risk. Annual digital dermoscopic follow-up in MF patients treated with UVA is advised for early diagnosis and treatment of secondary cutaneous malignancies.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10626422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01Epub Date: 2023-06-29DOI: 10.1111/phpp.12896
Marissa S Ceresnie, Jay Patel, Erika J Tvedten, Indermeet Kohli, Tasneem F Mohammad
Visible light (400– 700 nm), especially blue light, can produce erythema in all skin phototypes and longlasting changes in skin pigmentation in individuals with darker skin phototypes (SPT IVVI) when they are exposed to intensities and wavelengths similar to those from natural sun exposure.1– 5 In addition to the sun, electronic screens also emit blue light; however, they emit these wavelengths at much lower intensities— approximately three orders of magnitude lower than the corresponding intensities in sunlight. Notably, there is poor clinical evidence to substantiate adverse clinical effects from electronic blue light exposure.6,7 Despite this lack of evidence, there is public interest in the possible harmful effects of artificial blue light from electronic devices on the skin, and protection strategies against this specific source of blue light are being propagated and marketed in media outlets.8 As the public increasingly looks to social media as a source of medical information, awareness of its content is important for dermatologists to address medical misinformation. Our aim was to characterize the content contained in popular social media platforms about the sources of blue light likely to have clinical effects and blue light photoprotection strategies recommended on these platforms by different types of content creators. The top three social media platforms used for dermatologic information and product promotion were chosen based on the highest number of active users.9 Social media posts on TikTok, Instagram, and YouTube were identified using search terms or the hashtag “blue light skin damage” or “blue light skin” and were analyzed between December 2021 and January 2022. NonEnglish language, therapeutic and nondermatologic posts were excluded. Included posts were categorized into one of the following content creator categories based on the similarities of services verified on their profiles and websites: commercial industry, dermatology professional (dermatologist or dermatology physician assistant), esthetician, layperson, news source, nondermatologist physician, and selfidentified skin expert. Reported sources of blue light (sun, electronic screen, sun and screen, not mentioned) and proposed photoprotection measures (tinted, mineral, and other sunscreens; topical antioxidants; screen filter) were collected. Descriptive and chisquare tests of proportions were conducted in SAS 9.4. A total of 344 posts were identified: 70 (49.4%) from TikTok, 88 (25.6%) from Instagram, and 86 (25%) from YouTube. Most of the 344 posts were created by commercial industry (n = 102; 29.7%), followed by 71 laypeople (20.7%), 41 dermatology professionals (11.9%), 40 selfidentified skin experts (11.6%), 38 estheticians (11.0%), 35 nondermatology physicians (10.2%), and 17 news sources (4.9%). Of the 344 posts, more than half (n = 196; 57.0%) solely reported electronic screens as the source of blue light, whereas 28 (8.1%) reported sun and 87 (25.3%) reported bo
{"title":"Blue light and the skin on social media: An analysis of posts on exposure and photoprotection strategies.","authors":"Marissa S Ceresnie, Jay Patel, Erika J Tvedten, Indermeet Kohli, Tasneem F Mohammad","doi":"10.1111/phpp.12896","DOIUrl":"10.1111/phpp.12896","url":null,"abstract":"Visible light (400– 700 nm), especially blue light, can produce erythema in all skin phototypes and longlasting changes in skin pigmentation in individuals with darker skin phototypes (SPT IVVI) when they are exposed to intensities and wavelengths similar to those from natural sun exposure.1– 5 In addition to the sun, electronic screens also emit blue light; however, they emit these wavelengths at much lower intensities— approximately three orders of magnitude lower than the corresponding intensities in sunlight. Notably, there is poor clinical evidence to substantiate adverse clinical effects from electronic blue light exposure.6,7 Despite this lack of evidence, there is public interest in the possible harmful effects of artificial blue light from electronic devices on the skin, and protection strategies against this specific source of blue light are being propagated and marketed in media outlets.8 As the public increasingly looks to social media as a source of medical information, awareness of its content is important for dermatologists to address medical misinformation. Our aim was to characterize the content contained in popular social media platforms about the sources of blue light likely to have clinical effects and blue light photoprotection strategies recommended on these platforms by different types of content creators. The top three social media platforms used for dermatologic information and product promotion were chosen based on the highest number of active users.9 Social media posts on TikTok, Instagram, and YouTube were identified using search terms or the hashtag “blue light skin damage” or “blue light skin” and were analyzed between December 2021 and January 2022. NonEnglish language, therapeutic and nondermatologic posts were excluded. Included posts were categorized into one of the following content creator categories based on the similarities of services verified on their profiles and websites: commercial industry, dermatology professional (dermatologist or dermatology physician assistant), esthetician, layperson, news source, nondermatologist physician, and selfidentified skin expert. Reported sources of blue light (sun, electronic screen, sun and screen, not mentioned) and proposed photoprotection measures (tinted, mineral, and other sunscreens; topical antioxidants; screen filter) were collected. Descriptive and chisquare tests of proportions were conducted in SAS 9.4. A total of 344 posts were identified: 70 (49.4%) from TikTok, 88 (25.6%) from Instagram, and 86 (25%) from YouTube. Most of the 344 posts were created by commercial industry (n = 102; 29.7%), followed by 71 laypeople (20.7%), 41 dermatology professionals (11.9%), 40 selfidentified skin experts (11.6%), 38 estheticians (11.0%), 35 nondermatology physicians (10.2%), and 17 news sources (4.9%). Of the 344 posts, more than half (n = 196; 57.0%) solely reported electronic screens as the source of blue light, whereas 28 (8.1%) reported sun and 87 (25.3%) reported bo","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10627971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Pityriasis lichenoides (PL) is a papulosquamous disease affecting both children and adults, for which narrowband-UVB (NB-UVB) phototherapy is regarded as a commonly used treatment option. The aim of this study was to investigate the efficacy of NB-UVB phototherapy in the management of PL and to compare response rates in pediatric and adult age groups.
Materials and methods: This observational, retrospective study included 20 PL patients (12 pityriasis lichenoides chronica; PLC, 8 pityriasis lichenoides et varioliformis acuta; PLEVA) who failed to respond to other treatment modalities. The data for this study were collected retrospectively from patient follow-up forms in the phototherapy unit.
Results: A complete response (CR) was obtained in all pediatric patients with PL, while 53.8% of adult patients had achieved CR. The mean cumulative dose required to achieve the CR was higher in pediatric patients than adult patients with PL (p < .05). The CR was achieved in 6 (75%) of 8 PLEVA patients, while 8 (66.7%) of 12 PLC patients had reached to CR. The mean number of exposures for patients with PLC to achieve a CR was higher than patients with PLEVA (p < .05). Erythema was the most common adverse effect during phototherapy particularly in 5 (35.7%) of the patients with PL who had achieved CR.
Conclusions: NB-UVB is an effective and well-tolerated treatment option for PL especially in diffuse types. A higher response can be obtained in children with higher cumulative dose. Patients with PLC may require more exposures for CR than patients with PLEVA.
{"title":"Narrowband ultraviolet B phototherapy for pityriasis lichenoides: A real-life experience.","authors":"Esra Agaoglu, Hilal Kaya Erdogan, Ersoy Acer, Zeynep Nurhan Saracoglu, Muzaffer Bilgin","doi":"10.1111/phpp.12895","DOIUrl":"https://doi.org/10.1111/phpp.12895","url":null,"abstract":"<p><strong>Introduction: </strong>Pityriasis lichenoides (PL) is a papulosquamous disease affecting both children and adults, for which narrowband-UVB (NB-UVB) phototherapy is regarded as a commonly used treatment option. The aim of this study was to investigate the efficacy of NB-UVB phototherapy in the management of PL and to compare response rates in pediatric and adult age groups.</p><p><strong>Materials and methods: </strong>This observational, retrospective study included 20 PL patients (12 pityriasis lichenoides chronica; PLC, 8 pityriasis lichenoides et varioliformis acuta; PLEVA) who failed to respond to other treatment modalities. The data for this study were collected retrospectively from patient follow-up forms in the phototherapy unit.</p><p><strong>Results: </strong>A complete response (CR) was obtained in all pediatric patients with PL, while 53.8% of adult patients had achieved CR. The mean cumulative dose required to achieve the CR was higher in pediatric patients than adult patients with PL (p < .05). The CR was achieved in 6 (75%) of 8 PLEVA patients, while 8 (66.7%) of 12 PLC patients had reached to CR. The mean number of exposures for patients with PLC to achieve a CR was higher than patients with PLEVA (p < .05). Erythema was the most common adverse effect during phototherapy particularly in 5 (35.7%) of the patients with PL who had achieved CR.</p><p><strong>Conclusions: </strong>NB-UVB is an effective and well-tolerated treatment option for PL especially in diffuse types. A higher response can be obtained in children with higher cumulative dose. Patients with PLC may require more exposures for CR than patients with PLEVA.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10279940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Lysosomal cathepsin D (CTSD) can degrade internalized advanced glycation end products (AGEs) in dermal fibroblasts. CTSD expression is decreased in photoaged fibroblasts, which contributes to intracellular AGEs deposition and further plays a role in AGEs accumulation of photoaged skin. The mechanism under downregulated CTSD expression is unclear.
Objective: To explore possible mechanism of regulating CTSD expression in photoaged fibroblasts.
Methods: Dermal fibroblasts were induced into photoaging with repetitive ultraviolet A (UVA) irradiation. The competing endogenous RNA (ceRNA) networks were constructed to predict candidate circRNAs or miRNAs related with CTSD expression. AGEs-BSA degradation by fibroblasts was studied with flow cytometry, ELISA, and confocal microscopy. Effects of overexpressing circRNA-406918 via lentiviral transduction on CTSD expression, autophagy, AGE-BSA degradation were analyzed in photoaged fibroblasts. The correlation between circRNA-406918 and CTSD expression or AGEs accumulation in sun-exposed and sun-protected skin was studied.
Results: CTSD expression, autophagy, and AGEs-BSA degradation were significantly decreased in photoaged fibroblasts. CircRNA-406918 was identified to regulate CTSD expression, autophagy, and senescence in photoaged fibroblasts. Overexpressing circRNA-406918 potently decreased senescence and increased CTSD expression, autophagic flux, and AGEs-BSA degradation in photoaged fibroblasts. Moreover, circRNA-406918 level was positively correlated with CTSD mRNA expression and negatively associated with AGEs accumulation in photodamaged skin. Further, circRNA-406918 was predicted to mediate CTSD expression through sponging eight miRNAs.
Conclusion: These findings suggest that circRNA-406918 regulates CTSD expression and AGEs degradation in UVA-induced photoaged fibroblasts and might exert a role in AGEs accumulation in photoaged skin.
{"title":"CircRNA-406918 enhances the degradation of advanced glycation end products in photoaged human dermal fibroblasts via targeting cathepsin D.","authors":"Yingying Qu, Mengyao Wang, Jingjing Lan, Xianyin Huang, Jingxi Huang, Hongpeng Li, Yue Zheng, Qingfang Xu","doi":"10.1111/phpp.12887","DOIUrl":"10.1111/phpp.12887","url":null,"abstract":"<p><strong>Background: </strong>Lysosomal cathepsin D (CTSD) can degrade internalized advanced glycation end products (AGEs) in dermal fibroblasts. CTSD expression is decreased in photoaged fibroblasts, which contributes to intracellular AGEs deposition and further plays a role in AGEs accumulation of photoaged skin. The mechanism under downregulated CTSD expression is unclear.</p><p><strong>Objective: </strong>To explore possible mechanism of regulating CTSD expression in photoaged fibroblasts.</p><p><strong>Methods: </strong>Dermal fibroblasts were induced into photoaging with repetitive ultraviolet A (UVA) irradiation. The competing endogenous RNA (ceRNA) networks were constructed to predict candidate circRNAs or miRNAs related with CTSD expression. AGEs-BSA degradation by fibroblasts was studied with flow cytometry, ELISA, and confocal microscopy. Effects of overexpressing circRNA-406918 via lentiviral transduction on CTSD expression, autophagy, AGE-BSA degradation were analyzed in photoaged fibroblasts. The correlation between circRNA-406918 and CTSD expression or AGEs accumulation in sun-exposed and sun-protected skin was studied.</p><p><strong>Results: </strong>CTSD expression, autophagy, and AGEs-BSA degradation were significantly decreased in photoaged fibroblasts. CircRNA-406918 was identified to regulate CTSD expression, autophagy, and senescence in photoaged fibroblasts. Overexpressing circRNA-406918 potently decreased senescence and increased CTSD expression, autophagic flux, and AGEs-BSA degradation in photoaged fibroblasts. Moreover, circRNA-406918 level was positively correlated with CTSD mRNA expression and negatively associated with AGEs accumulation in photodamaged skin. Further, circRNA-406918 was predicted to mediate CTSD expression through sponging eight miRNAs.</p><p><strong>Conclusion: </strong>These findings suggest that circRNA-406918 regulates CTSD expression and AGEs degradation in UVA-induced photoaged fibroblasts and might exert a role in AGEs accumulation in photoaged skin.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10281692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: Ultraviolet-induced skin photoaging was involved in DNA oxidative damage. Specnuezhenide, one of the secoiridoids extracted from Ligustri Lucidi Fructus, possesses antioxidant and anti-inflammatory effects. Whether specnuezhenide ameliorates skin photoaging remains unclear. This study aimed to investigate the effect of specnuezhenide on skin photoaging induced by ultraviolet and explore the underlying mechanism.
Methods: Mice were employed to treat with ultraviolet to induce skin photoaging, then administrated 10 and 20 mg/kg of specnuezhenide. Histological analysis, protein expression, network pharmacology, and autodock analysis were conducted.
Results: Specnuezhenide ameliorated ultraviolet-induced skin photoaging in mice via the increase in collagen contents, and decrease in epidermal thickness, malondialdehyde content, and β-galactosidase expression in the skin. Specnuezhenide reduced cutaneous apoptosis and inflammation in mice with skin photoaging. In addition, network pharmacology data indicated that specnuezhenide possessed potential targets on the NOD-like receptor signaling pathway. Validation experiment found that specnuezhenide inhibited the expression of NOD-like receptor family pyrin domain-containing 3, gasdermin D-C1, and Caspase 1. Furthermore, the expression of 8-Oxoguanine DNA glycosylase (OGG1), sirtuin 3 (SIRT3), and superoxide dismutase 2 was increased in specnuezhenide-treated mice with photoaging.
Conclusion: Specnuezhenide protected against ultraviolet-induced skin photoaging in mice via a probable activation of SIRT3/OGG1 signal.
{"title":"Specnuezhenide ameliorates ultraviolet-induced skin photoaging in mice by regulating the Sirtuin 3/8-Oxoguanine DNA glycosylase signal.","authors":"Nan Tang, Ying-Yun Ren, Hao-Tian Wu, Xi-Ting Lv, Xiao-Ting Liu, Qi-Lin Li, Guo-En Wang, Yan-Hua Wu","doi":"10.1111/phpp.12880","DOIUrl":"https://doi.org/10.1111/phpp.12880","url":null,"abstract":"<p><strong>Purpose: </strong>Ultraviolet-induced skin photoaging was involved in DNA oxidative damage. Specnuezhenide, one of the secoiridoids extracted from Ligustri Lucidi Fructus, possesses antioxidant and anti-inflammatory effects. Whether specnuezhenide ameliorates skin photoaging remains unclear. This study aimed to investigate the effect of specnuezhenide on skin photoaging induced by ultraviolet and explore the underlying mechanism.</p><p><strong>Methods: </strong>Mice were employed to treat with ultraviolet to induce skin photoaging, then administrated 10 and 20 mg/kg of specnuezhenide. Histological analysis, protein expression, network pharmacology, and autodock analysis were conducted.</p><p><strong>Results: </strong>Specnuezhenide ameliorated ultraviolet-induced skin photoaging in mice via the increase in collagen contents, and decrease in epidermal thickness, malondialdehyde content, and β-galactosidase expression in the skin. Specnuezhenide reduced cutaneous apoptosis and inflammation in mice with skin photoaging. In addition, network pharmacology data indicated that specnuezhenide possessed potential targets on the NOD-like receptor signaling pathway. Validation experiment found that specnuezhenide inhibited the expression of NOD-like receptor family pyrin domain-containing 3, gasdermin D-C1, and Caspase 1. Furthermore, the expression of 8-Oxoguanine DNA glycosylase (OGG1), sirtuin 3 (SIRT3), and superoxide dismutase 2 was increased in specnuezhenide-treated mice with photoaging.</p><p><strong>Conclusion: </strong>Specnuezhenide protected against ultraviolet-induced skin photoaging in mice via a probable activation of SIRT3/OGG1 signal.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10644426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Corinne Granger, Thierry Passeron, Carles Trullas, Muzzammil Hosenally, Bibi Nusayha Sokeechand, Jean Krutmann, Henry W Lim
Background: Two previously published clinical studies by our group assessed erythema and pigmentation responses in outdoor conditions with three reference sunscreens, comparing their effectiveness under the full spectrum of natural sunlight. These studies followed an almost identical protocol but were conducted in two different locations and in two ethnic groups: broadly, Chinese (Singapore) and White European (Mauritius). We analysed the data from these two study populations to compare differences in skin response according to ethnicity.
Methods: The analysis included 128 subjects (53 were Chinese from Singapore and 75 were White European from Mauritius and Singapore). Products used were the reference sunscreens P3 (sun protection factor [SPF] 15), P5 (SPF 30) and P8 (SPF 50+) from ISO norm 24444:2019. Participants were exposed to outdoor sunlight for 2-3 h, depending on baseline ITA. Endpoints were erythema at 24 h: clinical score and colorimetry (Δa*) and pigmentation at 1 week based on colorimetry (ΔL* and ΔITA).
Results: Among those with baseline ITA > 41, there were differences in erythemal response between the Chinese and White European groups, the White European group being more erythematous and also having a higher rate of photoprotection failure particularly at SPFs 15 and 30.
Conclusion: Differences in skin response to sun influenced by ethnicity should be taken into account when making recommendations on sun safety.
{"title":"Outdoor clinical testing with reference sunscreens to determine differences in skin response between populations of different ethnicity: A combined data analysis from 128 subjects.","authors":"Corinne Granger, Thierry Passeron, Carles Trullas, Muzzammil Hosenally, Bibi Nusayha Sokeechand, Jean Krutmann, Henry W Lim","doi":"10.1111/phpp.12871","DOIUrl":"https://doi.org/10.1111/phpp.12871","url":null,"abstract":"<p><strong>Background: </strong>Two previously published clinical studies by our group assessed erythema and pigmentation responses in outdoor conditions with three reference sunscreens, comparing their effectiveness under the full spectrum of natural sunlight. These studies followed an almost identical protocol but were conducted in two different locations and in two ethnic groups: broadly, Chinese (Singapore) and White European (Mauritius). We analysed the data from these two study populations to compare differences in skin response according to ethnicity.</p><p><strong>Methods: </strong>The analysis included 128 subjects (53 were Chinese from Singapore and 75 were White European from Mauritius and Singapore). Products used were the reference sunscreens P3 (sun protection factor [SPF] 15), P5 (SPF 30) and P8 (SPF 50+) from ISO norm 24444:2019. Participants were exposed to outdoor sunlight for 2-3 h, depending on baseline ITA. Endpoints were erythema at 24 h: clinical score and colorimetry (Δa*) and pigmentation at 1 week based on colorimetry (ΔL* and ΔITA).</p><p><strong>Results: </strong>Among those with baseline ITA > 41, there were differences in erythemal response between the Chinese and White European groups, the White European group being more erythematous and also having a higher rate of photoprotection failure particularly at SPFs 15 and 30.</p><p><strong>Conclusion: </strong>Differences in skin response to sun influenced by ethnicity should be taken into account when making recommendations on sun safety.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10277414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Corrado Zengarini, Gregorio Barufaldi, Bianca Maria Piraccini, Federico Bardazzi, Martina Mussi, Bor Hrvatin, Alessandro Pileri
Introduction: Mycosis fungoides (MF) and Sezary Syndrome are the most common forms of cutaneous T-cell lymphoma. Early-stage MF is known to have an indolent behavior, and the EORTC guidelines recommend treating patients with skin-directed therapies, such as phototherapy, instead of systemic therapies. Phototherapy is a popular therapeutic option, with two commonly used light sources-PUVA and narrow band-nb UVB. PUVA is less commonly used due to its potential carcinogenic role, but it has systemic effects, while nb-UVB has mostly skin-limited effects. There is ongoing debate regarding the role of UVB light, and in 2021, the Cutaneous Lymphoma Italian Study Group reached a consensus on technical schedules for NB-UVB and PUVA for MF. This study aims to analyze and compare the efficacy of the two phototherapy options in treating early-MF patients.
Materials and methods: The study included patients diagnosed with stage IA/B MF in the last 10 years, who had at least 12 months of follow-up data and a minimum of 24 phototherapy sessions (PUVA or nb UVB) and treated with topical steroids apart from phototherapy.
Results: Results showed that the two phototherapy options were similarly effective in treating early MF, with no significant differences in clinical response, although PUVA was associated with more adverse effects.
Conclusions: The study provides valuable insights into the use of phototherapy in early MF, and the results can be used to guide treatment decisions and improve patient outcomes.
{"title":"Nb-UVB and PUVA therapy in treating early stages of Mycosis Fungoides: A single-center cross-sectional study.","authors":"Corrado Zengarini, Gregorio Barufaldi, Bianca Maria Piraccini, Federico Bardazzi, Martina Mussi, Bor Hrvatin, Alessandro Pileri","doi":"10.1111/phpp.12873","DOIUrl":"https://doi.org/10.1111/phpp.12873","url":null,"abstract":"<p><strong>Introduction: </strong>Mycosis fungoides (MF) and Sezary Syndrome are the most common forms of cutaneous T-cell lymphoma. Early-stage MF is known to have an indolent behavior, and the EORTC guidelines recommend treating patients with skin-directed therapies, such as phototherapy, instead of systemic therapies. Phototherapy is a popular therapeutic option, with two commonly used light sources-PUVA and narrow band-nb UVB. PUVA is less commonly used due to its potential carcinogenic role, but it has systemic effects, while nb-UVB has mostly skin-limited effects. There is ongoing debate regarding the role of UVB light, and in 2021, the Cutaneous Lymphoma Italian Study Group reached a consensus on technical schedules for NB-UVB and PUVA for MF. This study aims to analyze and compare the efficacy of the two phototherapy options in treating early-MF patients.</p><p><strong>Materials and methods: </strong>The study included patients diagnosed with stage IA/B MF in the last 10 years, who had at least 12 months of follow-up data and a minimum of 24 phototherapy sessions (PUVA or nb UVB) and treated with topical steroids apart from phototherapy.</p><p><strong>Results: </strong>Results showed that the two phototherapy options were similarly effective in treating early MF, with no significant differences in clinical response, although PUVA was associated with more adverse effects.</p><p><strong>Conclusions: </strong>The study provides valuable insights into the use of phototherapy in early MF, and the results can be used to guide treatment decisions and improve patient outcomes.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10281160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Vitamin D analogues and NBUVB are both well-recognised modes of therapy in the treatment of chronic stable plaque psoriasis. The objective of this open label intraindividual, left right study was to compare two different vitamin D analogues, calcipotriol and calcitriol, in combination with NBUVB phototherapy in psoriasis.
Methods: Thirty patients with stable plaque psoriasis were enrolled for a 12-week clinical trial. The target lesion on the left side was treated topically with calcitriol ointment, while that on the right side was treated with calcipotriol ointment once daily. The whole body was irradiated with narrow-band ultraviolet B phototherapy (NBUVB) three times per week. Efficacy was assessed by target plaque scoring.
Results: Both therapies resulted in a statistically significant reduction in erythema, scaling, thickness, and target plaque score, seen as early as 2 weeks into therapy. However, the calcipotriol combination led to an earlier clearance of plaques and a lesser relapse rate than the calcitriol combination. The number of treatment sessions and cumulative NBUVB doses were significantly lower in the calcipotriol-treated group.
Conclusion: Both vitamin D analogues appear to be safe, effective, and cosmetically acceptable, with calcipotriol being more efficacious, well tolerated, with a rapid onset of action and a better maintenance of response.
{"title":"Comparative evaluation of efficacy and safety of calcipotriol versus calcitriol ointment, both in combination with narrow-band ultraviolet B phototherapy in the treatment of stable plaque psoriasis.","authors":"Disha Chakraborty, Kamal Aggarwal","doi":"10.1111/phpp.12893","DOIUrl":"https://doi.org/10.1111/phpp.12893","url":null,"abstract":"<p><strong>Background: </strong>Vitamin D analogues and NBUVB are both well-recognised modes of therapy in the treatment of chronic stable plaque psoriasis. The objective of this open label intraindividual, left right study was to compare two different vitamin D analogues, calcipotriol and calcitriol, in combination with NBUVB phototherapy in psoriasis.</p><p><strong>Methods: </strong>Thirty patients with stable plaque psoriasis were enrolled for a 12-week clinical trial. The target lesion on the left side was treated topically with calcitriol ointment, while that on the right side was treated with calcipotriol ointment once daily. The whole body was irradiated with narrow-band ultraviolet B phototherapy (NBUVB) three times per week. Efficacy was assessed by target plaque scoring.</p><p><strong>Results: </strong>Both therapies resulted in a statistically significant reduction in erythema, scaling, thickness, and target plaque score, seen as early as 2 weeks into therapy. However, the calcipotriol combination led to an earlier clearance of plaques and a lesser relapse rate than the calcitriol combination. The number of treatment sessions and cumulative NBUVB doses were significantly lower in the calcipotriol-treated group.</p><p><strong>Conclusion: </strong>Both vitamin D analogues appear to be safe, effective, and cosmetically acceptable, with calcipotriol being more efficacious, well tolerated, with a rapid onset of action and a better maintenance of response.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10663625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01Epub Date: 2023-05-18DOI: 10.1111/phpp.12888
Alvaro Prados-Carmona, Ricardo Ruiz-Villaverde, María Victoria de Gálvez Aranda, José Aguilera Arjona, Francisco J Navarro-Triviño
Chronic actinic dermatitis (CAD) is an infrequent and underdiagnosed photodermatosis mostly reported in adult men. There are still unmet therapeutic needs regarding this condition, forcing us to look for offlabel alternatives. A 62yearold construction worker came to our Contact Eczema and Immunoallergic Department with severe hyperkeratotic plaques in sunexposed areas. He had been suffering from chronic lesions on the dorsal side of his hands, knees, elbows, and upper back for 12 years that had progressively become lichenified (Figure 1). The condition drastically worsened over holiday periods, including an erythrodermic episode at the onset of the disease which happened over summer. He had been treating his disease with both topical and systemic corticosteroids on a regular basis since it first appeared. He had no other medical comorbidities and had repetitively been patch tested with negative results (European, acrylate, epoxy resin, and plant series— Chemotechnique Diagnostics) according to the criteria of the International Contact Dermatitis Research Group (ICDRG) on Day (D) 2, D4, and D7. Several skin biopsies were taken over time showing acanthosis, spongiosis, deep dermal lymphocytic infiltration (CD4:CD8 ratio was 1:1), lichenification, and prominent multinucleated dermal dendrocytes. None of the biopsies showed monoclonal gammaTcell receptor rearrangement. Photopatch test (including compositae mix and Sesquiterpene lactones) was negative. The photobiology study (Dermatologic Photobiology and DermatoOncology Laboratory, Photodiagnosis Unit, University of Málaga, Spain) elicited intense erythema to UVA (2 min, 44 J/cm2; PhoenixMH150 W/TD/NDL) and UVB (minimal erythema dose 9.3 mJ/cm2; dermalight 80UVB device [normal range: 25– 30 mJ/cm2 for his skin type: Fitzpatrick 2]), enabling the diagnosis of CAD. The patient started a hardening regimen with UVA1 phototherapy which had to be abruptly stopped due to excessive erythema and incoercible pruritus right after the sessions. Apart from strict solar protection, sun avoidance measures, topical corticosteroids, and emollients, we prescribed azathioprine 2 mg/kg a day. Unfortunately, this treatment had to be suspended within 1 month following severe hypertransaminasemia. Methotrexate 15 mg a week induced unbearable gastrointestinal side effects. Acitretin achieved some improvement with a dosage between 25 and 35 mg a day but after 2 months it was abandoned due to headaches that were uncontrollable with conventional analgesics. Alternatively, we prescribed alitretinoin 30 mg a day, providing significant symptomatic relief and improvement of his poikilodermatous appearance. Eight months after starting the treatment, the patient's condition had almost completely resolved (Figure 2), with no clinical or analytical side effects. NRS scale was 2 down from 10. Chronic actinic dermatitis consists of an immune reaction against elicited cutaneous antigens.1 This reaction induces inflammation of skin areas
{"title":"Successful treatment of chronic actinic dermatitis with alitretinoin: Should retinoids be included in the therapeutical arsenal?","authors":"Alvaro Prados-Carmona, Ricardo Ruiz-Villaverde, María Victoria de Gálvez Aranda, José Aguilera Arjona, Francisco J Navarro-Triviño","doi":"10.1111/phpp.12888","DOIUrl":"10.1111/phpp.12888","url":null,"abstract":"Chronic actinic dermatitis (CAD) is an infrequent and underdiagnosed photodermatosis mostly reported in adult men. There are still unmet therapeutic needs regarding this condition, forcing us to look for offlabel alternatives. A 62yearold construction worker came to our Contact Eczema and Immunoallergic Department with severe hyperkeratotic plaques in sunexposed areas. He had been suffering from chronic lesions on the dorsal side of his hands, knees, elbows, and upper back for 12 years that had progressively become lichenified (Figure 1). The condition drastically worsened over holiday periods, including an erythrodermic episode at the onset of the disease which happened over summer. He had been treating his disease with both topical and systemic corticosteroids on a regular basis since it first appeared. He had no other medical comorbidities and had repetitively been patch tested with negative results (European, acrylate, epoxy resin, and plant series— Chemotechnique Diagnostics) according to the criteria of the International Contact Dermatitis Research Group (ICDRG) on Day (D) 2, D4, and D7. Several skin biopsies were taken over time showing acanthosis, spongiosis, deep dermal lymphocytic infiltration (CD4:CD8 ratio was 1:1), lichenification, and prominent multinucleated dermal dendrocytes. None of the biopsies showed monoclonal gammaTcell receptor rearrangement. Photopatch test (including compositae mix and Sesquiterpene lactones) was negative. The photobiology study (Dermatologic Photobiology and DermatoOncology Laboratory, Photodiagnosis Unit, University of Málaga, Spain) elicited intense erythema to UVA (2 min, 44 J/cm2; PhoenixMH150 W/TD/NDL) and UVB (minimal erythema dose 9.3 mJ/cm2; dermalight 80UVB device [normal range: 25– 30 mJ/cm2 for his skin type: Fitzpatrick 2]), enabling the diagnosis of CAD. The patient started a hardening regimen with UVA1 phototherapy which had to be abruptly stopped due to excessive erythema and incoercible pruritus right after the sessions. Apart from strict solar protection, sun avoidance measures, topical corticosteroids, and emollients, we prescribed azathioprine 2 mg/kg a day. Unfortunately, this treatment had to be suspended within 1 month following severe hypertransaminasemia. Methotrexate 15 mg a week induced unbearable gastrointestinal side effects. Acitretin achieved some improvement with a dosage between 25 and 35 mg a day but after 2 months it was abandoned due to headaches that were uncontrollable with conventional analgesics. Alternatively, we prescribed alitretinoin 30 mg a day, providing significant symptomatic relief and improvement of his poikilodermatous appearance. Eight months after starting the treatment, the patient's condition had almost completely resolved (Figure 2), with no clinical or analytical side effects. NRS scale was 2 down from 10. Chronic actinic dermatitis consists of an immune reaction against elicited cutaneous antigens.1 This reaction induces inflammation of skin areas ","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10331599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01Epub Date: 2023-05-31DOI: 10.1111/phpp.12890
D Mancha, P Filipe
Dear Editor, Artificial intelligence (AI) based on machine learning and convolutional neuron networks is rapidly becoming a realistic prospect in Dermatology.1,2 Due to the unique nature of Dermatology, AIaided dermatological diagnosis based on image recognition has become a current focus and future trend.3 In recent studies, AI algorithms have shown promising results for diagnosing nonmelanoma skin cancer and melanoma, with a diagnostic accuracy comparable with that of skin experts.1– 3 The use of 3D imaging systems allows clinicians to screen and label skinpigmented lesions and distributed disorders, which can provide an objective assessment and image documentation of lesion sites.3 Dermatoscopes combined with intelligent software help the dermatologist to easily correlate each closeup image with the corresponding marked lesions in the 3D body map.3 AI's emerging applications in Dermatology include diagnosing, managing, and monitoring other skin diseases, including inflammatory and autoimmune diseases.4,5 Phototherapy consists of the therapeutic use of ultraviolet radiation (UV). It can be performed with ultraviolet A (UVA) or ultraviolet B (UVB) radiation.6 The wavelengths administered and the UV radiation doses vary according to the proposed indication.7 Although psoriasis is the most frequent indication, it is used for atopic dermatitis, vitiligo, prurigo nodularis, cutaneous Tcell lymphoma, and cutaneous sclerosis.6,7 AI can revolutionize phototherapy in several ways. For example, AI algorithms could be developed to analyze patient data and provide an individualized phototherapy treatment by calculating the Minimum Erythematous Dose (MED) or according to the patient's phototype. It would therefore be of great help to use AI algorithms to provide personalized phototherapy protocols with optimal UV doses and exposure duration. Additionally, AI algorithms could be programmed to analyze the patient's skin response and adapt treatment. AI could monitor the patient's response to phototherapy in realtime by assessing disease severity scores8,9 (e.g., Psoriasis Area Severity Index, SCORing Atopic Dermatitis, Eczema Area and Severity Index, Prurigo Activity and Severity Score), calculating affected body surface8,9 area and detecting skin cancers.3 This could help to optimize the treatment and ensure better results. Additionally, AI could suggest alternative therapeutic strategies or combined topical and systemic therapies in case of phototherapy failure and acute phototoxic adverse effects. Emma et al.,10 used machine learning to determine which psoriasis patient characteristics are associated with longterm responses to biologics. From the same perspective, AI can be used to analyze large datasets of patient information and identify patterns that can help predict phototherapy's effectiveness for specific conditions. In the near future, AI can help clinicians make better treatment decisions and improve patient outcomes. Artificial Intelligence in Hea
{"title":"Phototherapy in the artificial intelligence era.","authors":"D Mancha, P Filipe","doi":"10.1111/phpp.12890","DOIUrl":"10.1111/phpp.12890","url":null,"abstract":"Dear Editor, Artificial intelligence (AI) based on machine learning and convolutional neuron networks is rapidly becoming a realistic prospect in Dermatology.1,2 Due to the unique nature of Dermatology, AIaided dermatological diagnosis based on image recognition has become a current focus and future trend.3 In recent studies, AI algorithms have shown promising results for diagnosing nonmelanoma skin cancer and melanoma, with a diagnostic accuracy comparable with that of skin experts.1– 3 The use of 3D imaging systems allows clinicians to screen and label skinpigmented lesions and distributed disorders, which can provide an objective assessment and image documentation of lesion sites.3 Dermatoscopes combined with intelligent software help the dermatologist to easily correlate each closeup image with the corresponding marked lesions in the 3D body map.3 AI's emerging applications in Dermatology include diagnosing, managing, and monitoring other skin diseases, including inflammatory and autoimmune diseases.4,5 Phototherapy consists of the therapeutic use of ultraviolet radiation (UV). It can be performed with ultraviolet A (UVA) or ultraviolet B (UVB) radiation.6 The wavelengths administered and the UV radiation doses vary according to the proposed indication.7 Although psoriasis is the most frequent indication, it is used for atopic dermatitis, vitiligo, prurigo nodularis, cutaneous Tcell lymphoma, and cutaneous sclerosis.6,7 AI can revolutionize phototherapy in several ways. For example, AI algorithms could be developed to analyze patient data and provide an individualized phototherapy treatment by calculating the Minimum Erythematous Dose (MED) or according to the patient's phototype. It would therefore be of great help to use AI algorithms to provide personalized phototherapy protocols with optimal UV doses and exposure duration. Additionally, AI algorithms could be programmed to analyze the patient's skin response and adapt treatment. AI could monitor the patient's response to phototherapy in realtime by assessing disease severity scores8,9 (e.g., Psoriasis Area Severity Index, SCORing Atopic Dermatitis, Eczema Area and Severity Index, Prurigo Activity and Severity Score), calculating affected body surface8,9 area and detecting skin cancers.3 This could help to optimize the treatment and ensure better results. Additionally, AI could suggest alternative therapeutic strategies or combined topical and systemic therapies in case of phototherapy failure and acute phototoxic adverse effects. Emma et al.,10 used machine learning to determine which psoriasis patient characteristics are associated with longterm responses to biologics. From the same perspective, AI can be used to analyze large datasets of patient information and identify patterns that can help predict phototherapy's effectiveness for specific conditions. In the near future, AI can help clinicians make better treatment decisions and improve patient outcomes. Artificial Intelligence in Hea","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10278490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}